Nestlé and NTU Singapore to establish research lab focusing on longevity, women’s health
This multi‑year partnership will bring together Nestlé’s global research capabilities and local expertise built through its R&D center…
Genentech petrelintide sheds 10.7% weight in Phase II
03/05/2026 – 01:45 PM – Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus…
Roche, Zealand shares fall on ‘undifferentiated’ obesity drug results
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free…
Roche’s Weight-Loss Ambitions Face Reality Check
Roche’s Petrelintide shows 9% net weight loss in Phase II, missing high expectations. Stock and partner Zealand Pharma…
Roche and Zealand’s Phase II obesity trial divides analyst opinion
Roche and Zealand Pharma’s co-developed amylin analogue, petrelintide, has met its primary endpoint in a Phase II trial,…
Better Weight Loss Stock: Novo Nordisk Vs. Amgen
Key Points Novo Nordisk is a top player in the weight loss market and has several more products…
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
F. Hoffmann-La Roche Ltd Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7%…
2 Underrated Weight Loss Stocks to Buy Now
Key Points Regeneron has a pair of weight-loss candidates close to entering late-stage studies. Roche’s recent mid-stage readout…
Roche Phase II weight-loss drug trims 10.7% vs placebo
Roche (OTCQX: RHHBY) reported positive Phase II ZUPREME-1 topline results for petrelintide, an…
Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal
Roche RHHBY has announced that the mid-stage study ZUPREME-1, evaluating the investigational candidate petrelintide for the treatment of…
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
F. Hoffmann-La Roche Ltd Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7%…
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
F. Hoffmann-La Roche Ltd Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7%…